Wegovy cost without insurance in 2026: cheapest legitimate paths

What Wegovy actually costs at retail

Cash price at a retail pharmacy in 2026 is approximately $1,349 for a 28-day supply at any dose (0.25mg through 2.4mg). The pricing is dose-independent — a starting-dose pen costs the same as the maintenance-dose pen. GoodRx and other discount cards offer modest savings (sometimes 5-10%) but not the dramatic discounts that work for older generic drugs.

Insurance with prior authorization typically reduces this to $0-50/month copay, but for cash-pay patients there are several paths that beat retail substantially.

Path 1: NovoCare self-pay program ($349/mo)

Novo Nordisk's NovoCare self-pay program offers Wegovy at $349/month through NovoCare Pharmacy. New patients pay $199/month for their first two fills of 0.25 mg and 0.5 mg through December 31, 2026. Wegovy HD is $399/month, and the Wegovy pill is $149-299/month by dose. You need a valid prescription; insurance is not required.

Application: apply at novocare.com. Once approved, the program ships Wegovy directly to you on a monthly schedule. You can pause or cancel at any time.

Trade-offs: $349/month is real money. The program may be discontinued or repriced by Novo at any time. If you become eligible for insurance later, you'd need to transition off NovoCare.

Path 2: Foundayo (orforglipron) via LillyDirect ($149-299/mo)

FDA-approved on April 1, 2026 for chronic weight management, Foundayo (orforglipron) is Eli Lilly's once-daily GLP-1 pill. LillyDirect self-pay is $149/month for 0.8 mg and 2.5 mg, $199 for 5.5 mg, and $299 for 9 mg, 14.5 mg, and 17.2 mg. The 2.5 mg and 5.5 mg prices are introductory through December 31, 2026, and the 14.5 mg and 17.2 mg price requires a refill within 45 days.

Efficacy: 11.2% mean weight loss at 72 weeks on the top dose in ATTAIN-1, versus 2.1% on placebo. That is below injectable Wegovy (about 15% in STEP-1) and injectable tirzepatide (about 21% in SURMOUNT-1).

Application: your prescriber writes a Foundayo prescription and you fill it through LillyDirect. It is a daily pill taken with or without food, with no injection.

Trade-offs: not the same drug as Wegovy. If you've established response on injectable semaglutide and want continuity, switching is a clinical decision.

Path 3: Compounded semaglutide (narrowing legal grey zone)

During the 2022-2024 FDA shortage period, Hims, telehealth platforms, and many independent compounders sold compounded semaglutide at substantial cost reductions versus branded Wegovy.

Current status (2026): the FDA declared the shortage resolved in late 2024 and proposed permanently removing semaglutide from the 503B bulk-compounding list on April 30, 2026. Public comment period closes June 29, 2026. Hims exited compounded GLP-1 prescribing in February 2026 amid Novo Nordisk lawsuit pressure. Many compounders have followed.

If still available in your state, compounded semaglutide may still be the cheapest path — but the legal viability is winding down. Don't build a long-term plan around it. Quality varies by compounding pharmacy. The FDA has documented dosing errors and contamination concerns in some compounded products.

Path 4: Insurance appeal even if denied

Many self-pay patients have insurance that initially denies Wegovy coverage. Often this is appealable. Our appeal letter generator can produce a personalized letter based on the specific denial reason. No carrier publishes appeal success rates, but well-documented appeals routinely succeed.

Common appeals that work: medical-necessity documentation with BMI + comorbidities + prior lifestyle attempts; formulary exception requests citing FDA-approved indication; step-therapy override based on prior failure of cheaper alternatives.

Worth the effort even if currently paying NovoCare $349/mo: a successful insurance appeal can drop your cost to a $25/mo copay, saving about $3,900/year.

What about generic semaglutide?

Novo Nordisk's patent on semaglutide protects against generic manufacture in the US until approximately 2031-2032. No FDA-approved generic exists. Anything marketed as 'generic semaglutide' in the US in 2026 is either compounded (different regulatory category, not a true generic) or illegal (unapproved bulk imports).

Beware of online sellers offering 'generic semaglutide' at very low prices ($30-80/month). These are typically illegal imports of unapproved bulk material. Quality, dosing, sterility unverified. Don't risk it.